Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bushi Wang

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolismManuela Albisetti, Branislav Biss, Lisa Bomgaars, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and designMatteo Luciani, Manuela Albisetti, Branislav Biss, et al.
Clinical Lung Cancer|July 22, 2017
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based ChemotherapyEnriqueta Felip, Vera Hirsh, Sanjay Popat, et al.
Thrombosis and Haemostasis|May 29, 2015
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranCharles V Pollack, Paul A Reilly, Richard Bernstein, et al.
The Lancet. Oncology|July 10, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialJean-Charles Soria, Enriqueta Felip, Manuel Cobo, et al.
The New England Journal of Medicine|June 23, 2015
Idarucizumab for Dabigatran ReversalCharles V Pollack, Paul A Reilly, John Eikelboom, et al.
The New England Journal of Medicine|July 12, 2017
Idarucizumab for Dabigatran Reversal - Full Cohort AnalysisCharles V Pollack, Paul A Reilly, Joanne van Ryn, et al.
JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolismManuela Albisetti, Branislav Biss, Lisa Bomgaars, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and designMatteo Luciani, Manuela Albisetti, Branislav Biss, et al.
Clinical Lung Cancer|July 22, 2017
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based ChemotherapyEnriqueta Felip, Vera Hirsh, Sanjay Popat, et al.
Thrombosis and Haemostasis|May 29, 2015
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranCharles V Pollack, Paul A Reilly, Richard Bernstein, et al.
The Lancet. Oncology|July 10, 2015
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialJean-Charles Soria, Enriqueta Felip, Manuel Cobo, et al.
The New England Journal of Medicine|June 23, 2015
Idarucizumab for Dabigatran ReversalCharles V Pollack, Paul A Reilly, John Eikelboom, et al.
The New England Journal of Medicine|July 12, 2017
Idarucizumab for Dabigatran Reversal - Full Cohort AnalysisCharles V Pollack, Paul A Reilly, Joanne van Ryn, et al.
JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.
Pageof 2